| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 28 | 2021 | 739 | 3.770 |
Why?
|
| Proteomics | 22 | 2020 | 616 | 2.760 |
Why?
|
| Biomarkers, Tumor | 18 | 2021 | 1579 | 2.340 |
Why?
|
| Carcinoma, Pancreatic Ductal | 11 | 2021 | 195 | 2.300 |
Why?
|
| Proteome | 11 | 2021 | 287 | 2.220 |
Why?
|
| Lignans | 2 | 2026 | 7 | 1.870 |
Why?
|
| Biphenyl Compounds | 2 | 2026 | 75 | 1.800 |
Why?
|
| Colitis, Ulcerative | 8 | 2016 | 210 | 1.740 |
Why?
|
| Glioblastoma | 2 | 2026 | 371 | 1.390 |
Why?
|
| Apoptosis | 5 | 2026 | 1825 | 1.280 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2026 | 814 | 1.020 |
Why?
|
| Colorectal Neoplasms | 5 | 2016 | 616 | 0.990 |
Why?
|
| Glycoproteins | 9 | 2018 | 345 | 0.990 |
Why?
|
| Reactive Oxygen Species | 3 | 2026 | 523 | 0.950 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2026 | 8 | 0.950 |
Why?
|
| CDC2 Protein Kinase | 1 | 2026 | 36 | 0.930 |
Why?
|
| Neoplasm Proteins | 7 | 2020 | 679 | 0.920 |
Why?
|
| Camptothecin | 1 | 2026 | 76 | 0.920 |
Why?
|
| Adenocarcinoma | 10 | 2019 | 970 | 0.900 |
Why?
|
| Blood-Brain Barrier | 1 | 2025 | 152 | 0.860 |
Why?
|
| Cell Line, Tumor | 11 | 2026 | 3727 | 0.730 |
Why?
|
| Proteins | 4 | 2020 | 1006 | 0.720 |
Why?
|
| Pancreatic Juice | 3 | 2015 | 5 | 0.690 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 722 | 0.680 |
Why?
|
| Mitochondria | 1 | 2026 | 776 | 0.630 |
Why?
|
| Disease Progression | 9 | 2019 | 2195 | 0.620 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2014 | 587 | 0.620 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 22 | 0.610 |
Why?
|
| Mass Spectrometry | 10 | 2018 | 358 | 0.600 |
Why?
|
| Genes, Homeobox | 1 | 2019 | 61 | 0.590 |
Why?
|
| Cytoskeletal Proteins | 3 | 2012 | 260 | 0.580 |
Why?
|
| Drug Synergism | 3 | 2026 | 236 | 0.580 |
Why?
|
| Colon | 5 | 2016 | 366 | 0.560 |
Why?
|
| Metabolic Diseases | 1 | 2020 | 141 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2014 | 2016 | 0.550 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2019 | 125 | 0.550 |
Why?
|
| Phosphoproteins | 3 | 2012 | 448 | 0.540 |
Why?
|
| Diazooxonorleucine | 1 | 2017 | 1 | 0.530 |
Why?
|
| Deoxycytidine | 1 | 2017 | 80 | 0.510 |
Why?
|
| Glycomics | 1 | 2016 | 15 | 0.500 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 219 | 0.490 |
Why?
|
| Glutamine | 1 | 2017 | 201 | 0.470 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1304 | 0.470 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 555 | 0.470 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2026 | 46 | 0.470 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2008 | 219 | 0.460 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 830 | 0.440 |
Why?
|
| Body Fluids | 1 | 2015 | 45 | 0.440 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2012 | 105 | 0.430 |
Why?
|
| Colonic Neoplasms | 3 | 2016 | 262 | 0.430 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 43 | 0.430 |
Why?
|
| Carcinoma | 3 | 2018 | 283 | 0.430 |
Why?
|
| Cell Movement | 5 | 2014 | 875 | 0.420 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2012 | 157 | 0.420 |
Why?
|
| Carrier Proteins | 4 | 2017 | 996 | 0.420 |
Why?
|
| Rectum | 1 | 2014 | 102 | 0.420 |
Why?
|
| Cell Proliferation | 5 | 2019 | 2461 | 0.410 |
Why?
|
| Pancreatitis, Chronic | 3 | 2011 | 88 | 0.400 |
Why?
|
| Humans | 55 | 2026 | 130534 | 0.390 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 607 | 0.380 |
Why?
|
| Galectin 1 | 1 | 2012 | 1 | 0.370 |
Why?
|
| Immunohistochemistry | 10 | 2014 | 1592 | 0.370 |
Why?
|
| Precancerous Conditions | 3 | 2016 | 280 | 0.370 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 223 | 0.370 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 428 | 0.360 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 484 | 0.350 |
Why?
|
| Neoplasm Metastasis | 2 | 2012 | 713 | 0.350 |
Why?
|
| Pancreatitis | 3 | 2014 | 139 | 0.350 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 111 | 0.340 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 764 | 0.340 |
Why?
|
| Survival Analysis | 1 | 2014 | 1481 | 0.330 |
Why?
|
| Oxidation-Reduction | 2 | 2025 | 436 | 0.330 |
Why?
|
| Carcinoma in Situ | 2 | 2010 | 69 | 0.320 |
Why?
|
| MicroRNAs | 3 | 2016 | 888 | 0.320 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 253 | 0.320 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 420 | 0.320 |
Why?
|
| Cell Adhesion Molecules | 2 | 2016 | 222 | 0.310 |
Why?
|
| DNA Fingerprinting | 3 | 2005 | 106 | 0.300 |
Why?
|
| Peptidylprolyl Isomerase | 3 | 2014 | 33 | 0.290 |
Why?
|
| Genomic Instability | 2 | 2012 | 245 | 0.280 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1211 | 0.280 |
Why?
|
| Death-Associated Protein Kinases | 3 | 2020 | 4 | 0.270 |
Why?
|
| Signal Transduction | 8 | 2025 | 4664 | 0.270 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2008 | 71 | 0.270 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2008 | 101 | 0.270 |
Why?
|
| ras Proteins | 1 | 2008 | 140 | 0.270 |
Why?
|
| Thy-1 Antigens | 2 | 2020 | 18 | 0.260 |
Why?
|
| Glycosylation | 6 | 2021 | 126 | 0.260 |
Why?
|
| Fibroblasts | 1 | 2012 | 849 | 0.260 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 709 | 0.260 |
Why?
|
| Animals | 15 | 2026 | 33726 | 0.260 |
Why?
|
| Oxidative Stress | 4 | 2021 | 790 | 0.240 |
Why?
|
| HeLa Cells | 5 | 2014 | 688 | 0.240 |
Why?
|
| Allyl Compounds | 1 | 2026 | 5 | 0.240 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2019 | 359 | 0.240 |
Why?
|
| Prognosis | 4 | 2019 | 4866 | 0.230 |
Why?
|
| Down-Regulation | 4 | 2020 | 646 | 0.230 |
Why?
|
| Mice | 9 | 2026 | 18198 | 0.230 |
Why?
|
| Phosphorylation | 5 | 2020 | 1571 | 0.230 |
Why?
|
| Phenols | 1 | 2026 | 73 | 0.230 |
Why?
|
| Carcinogenesis | 2 | 2019 | 336 | 0.220 |
Why?
|
| Transcription Factors | 1 | 2014 | 2402 | 0.220 |
Why?
|
| Cell Survival | 4 | 2021 | 828 | 0.220 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2004 | 65 | 0.210 |
Why?
|
| Repressor Proteins | 1 | 2008 | 759 | 0.210 |
Why?
|
| ROC Curve | 4 | 2018 | 612 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 630 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 597 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2025 | 520 | 0.180 |
Why?
|
| Myeloid Cells | 2 | 2020 | 113 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2012 | 787 | 0.180 |
Why?
|
| Biopsy | 3 | 2016 | 1240 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 165 | 0.170 |
Why?
|
| Glycation End Products, Advanced | 1 | 2021 | 25 | 0.170 |
Why?
|
| Glyceraldehyde | 1 | 2021 | 28 | 0.170 |
Why?
|
| Osteoblasts | 1 | 2002 | 175 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2013 | 2596 | 0.160 |
Why?
|
| Aptamers, Nucleotide | 1 | 2020 | 37 | 0.160 |
Why?
|
| Stromal Cells | 2 | 2012 | 316 | 0.160 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 3 | 2014 | 30 | 0.150 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 124 | 0.150 |
Why?
|
| HT29 Cells | 2 | 2020 | 44 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 219 | 0.150 |
Why?
|
| Mutation | 7 | 2019 | 6064 | 0.150 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 416 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 70 | 0.150 |
Why?
|
| Nitric Oxide | 1 | 2002 | 465 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2012 | 699 | 0.140 |
Why?
|
| Cell Cycle | 2 | 2019 | 593 | 0.140 |
Why?
|
| Cell Line | 4 | 2014 | 2553 | 0.140 |
Why?
|
| Blotting, Western | 3 | 2010 | 1014 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 4 | 2005 | 1452 | 0.130 |
Why?
|
| DNA | 1 | 2003 | 1397 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2014 | 3353 | 0.130 |
Why?
|
| Inflammation | 1 | 2005 | 1481 | 0.130 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 393 | 0.130 |
Why?
|
| Peptide Library | 1 | 2017 | 56 | 0.130 |
Why?
|
| Tissue Array Analysis | 2 | 2014 | 136 | 0.130 |
Why?
|
| DNA Replication | 1 | 2019 | 355 | 0.130 |
Why?
|
| Neoplasms | 1 | 2012 | 2986 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1070 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 192 | 0.120 |
Why?
|
| Epidermal Growth Factor | 2 | 2008 | 115 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 974 | 0.120 |
Why?
|
| Amino Acid Sequence | 5 | 2014 | 2393 | 0.110 |
Why?
|
| HEK293 Cells | 2 | 2016 | 802 | 0.110 |
Why?
|
| Cyst Fluid | 1 | 2015 | 6 | 0.110 |
Why?
|
| DNA Methylation | 3 | 2016 | 1076 | 0.110 |
Why?
|
| Peptides | 2 | 2017 | 707 | 0.110 |
Why?
|
| Bile | 1 | 2015 | 44 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2016 | 177 | 0.110 |
Why?
|
| Pancreatic Cyst | 1 | 2015 | 28 | 0.110 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2014 | 13 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 662 | 0.110 |
Why?
|
| Blood Proteins | 2 | 2015 | 143 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 187 | 0.110 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2014 | 97 | 0.100 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 3465 | 0.100 |
Why?
|
| Plectin | 1 | 2013 | 6 | 0.100 |
Why?
|
| Models, Biological | 2 | 2012 | 1375 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2017 | 287 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 305 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2012 | 303 | 0.100 |
Why?
|
| Exosomes | 1 | 2013 | 60 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 1282 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 2016 | 403 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2013 | 58 | 0.090 |
Why?
|
| Tissue Fixation | 1 | 2013 | 38 | 0.090 |
Why?
|
| Endopeptidases | 1 | 2013 | 106 | 0.090 |
Why?
|
| Sumoylation | 1 | 2013 | 47 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2011 | 2896 | 0.090 |
Why?
|
| Cell-Matrix Junctions | 1 | 2012 | 8 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 253 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 826 | 0.090 |
Why?
|
| Middle Aged | 5 | 2019 | 28408 | 0.090 |
Why?
|
| Myofibroblasts | 1 | 2012 | 63 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2020 | 576 | 0.090 |
Why?
|
| Biological Specimen Banks | 1 | 2011 | 72 | 0.080 |
Why?
|
| Young Adult | 2 | 2019 | 10037 | 0.080 |
Why?
|
| Neoplastic Processes | 1 | 2010 | 6 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2290 | 0.080 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 11 | 0.080 |
Why?
|
| Mucoproteins | 1 | 2010 | 10 | 0.080 |
Why?
|
| Osteopontin | 1 | 2010 | 55 | 0.080 |
Why?
|
| Biomarkers | 3 | 2015 | 3367 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 329 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2008 | 2884 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5187 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 189 | 0.080 |
Why?
|
| DNA Primers | 3 | 2013 | 600 | 0.080 |
Why?
|
| Actins | 1 | 2012 | 320 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2010 | 136 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2012 | 1440 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2017 | 158 | 0.080 |
Why?
|
| Male | 6 | 2019 | 64613 | 0.070 |
Why?
|
| Catalytic Domain | 2 | 2011 | 160 | 0.070 |
Why?
|
| Pancreas | 4 | 2013 | 218 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2013 | 120 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 304 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1590 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6771 | 0.070 |
Why?
|
| Immunoblotting | 2 | 2013 | 292 | 0.070 |
Why?
|
| Aged | 3 | 2019 | 20885 | 0.060 |
Why?
|
| Time Factors | 2 | 2014 | 6175 | 0.060 |
Why?
|
| Female | 7 | 2019 | 70545 | 0.060 |
Why?
|
| Plasminogen | 1 | 2007 | 7 | 0.060 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2007 | 18 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 688 | 0.060 |
Why?
|
| Enzymes | 1 | 2007 | 44 | 0.060 |
Why?
|
| Adolescent | 2 | 2019 | 20889 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2006 | 53 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1815 | 0.060 |
Why?
|
| Adult | 5 | 2019 | 31114 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 977 | 0.060 |
Why?
|
| Fibrinogen | 1 | 2007 | 169 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 992 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2007 | 197 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 378 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 123 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-crk | 1 | 2004 | 1 | 0.060 |
Why?
|
| Paxillin | 1 | 2004 | 13 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2004 | 109 | 0.050 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2005 | 330 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 198 | 0.050 |
Why?
|
| Chemotaxis | 1 | 2004 | 59 | 0.050 |
Why?
|
| COS Cells | 1 | 2004 | 253 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 226 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2004 | 287 | 0.050 |
Why?
|
| Computational Biology | 3 | 2019 | 861 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 147 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2020 | 3812 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 358 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 742 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2017 | 233 | 0.050 |
Why?
|
| Protein Binding | 2 | 2020 | 1652 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 716 | 0.050 |
Why?
|
| Kinetics | 1 | 2004 | 1087 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 11013 | 0.050 |
Why?
|
| Centrosome | 2 | 2013 | 28 | 0.050 |
Why?
|
| Cycloheximide | 1 | 2002 | 40 | 0.050 |
Why?
|
| Lumican | 2 | 2012 | 3 | 0.050 |
Why?
|
| Keratan Sulfate | 2 | 2012 | 6 | 0.050 |
Why?
|
| Nitroprusside | 1 | 2002 | 35 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 53 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 64 | 0.040 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 2 | 2012 | 30 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 93 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2013 | 136 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2012 | 38 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2002 | 298 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2002 | 236 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2019 | 17634 | 0.040 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2020 | 6 | 0.040 |
Why?
|
| Skull | 1 | 2002 | 148 | 0.040 |
Why?
|
| Phosphoserine | 1 | 2020 | 38 | 0.040 |
Why?
|
| Caspase 8 | 1 | 2020 | 26 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2020 | 23 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2020 | 150 | 0.040 |
Why?
|
| Biodiversity | 1 | 2019 | 72 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2020 | 312 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2002 | 1023 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 1998 | 204 | 0.030 |
Why?
|
| Werner Syndrome | 1 | 1997 | 1 | 0.030 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 1997 | 5 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2080 | 0.030 |
Why?
|
| Mutagens | 1 | 1997 | 46 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 638 | 0.030 |
Why?
|
| Oncogenes | 1 | 2018 | 164 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 274 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1879 | 0.030 |
Why?
|
| Transfection | 2 | 2011 | 961 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 586 | 0.030 |
Why?
|
| DNA Helicases | 1 | 1997 | 238 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2016 | 48 | 0.030 |
Why?
|
| Rats | 1 | 2002 | 3374 | 0.030 |
Why?
|
| DNA, Satellite | 1 | 1995 | 15 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2016 | 86 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 2016 | 34 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 3425 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2018 | 313 | 0.030 |
Why?
|
| Genes, ras | 1 | 1995 | 95 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 81 | 0.030 |
Why?
|
| Heterozygote | 1 | 1997 | 721 | 0.030 |
Why?
|
| DNA Damage | 1 | 1998 | 509 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 122 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 254 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 209 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 324 | 0.030 |
Why?
|
| Colitis | 1 | 2016 | 165 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2014 | 23 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 24 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2014 | 43 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 283 | 0.030 |
Why?
|
| Software | 1 | 2019 | 733 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 130 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2014 | 109 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 947 | 0.020 |
Why?
|
| Chromosomal Instability | 1 | 2013 | 59 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2013 | 106 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 554 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2013 | 109 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 358 | 0.020 |
Why?
|
| Proto-Oncogenes | 2 | 2006 | 37 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1208 | 0.020 |
Why?
|
| Contrast Media | 1 | 2015 | 476 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2012 | 33 | 0.020 |
Why?
|
| Gelsolin | 1 | 2012 | 13 | 0.020 |
Why?
|
| Exonucleases | 1 | 2012 | 27 | 0.020 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2011 | 7 | 0.020 |
Why?
|
| Exoribonucleases | 1 | 2012 | 21 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1113 | 0.020 |
Why?
|
| Acinar Cells | 1 | 2011 | 10 | 0.020 |
Why?
|
| Versicans | 1 | 2011 | 15 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 927 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 404 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2012 | 56 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 765 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2011 | 58 | 0.020 |
Why?
|
| Algorithms | 1 | 2018 | 1669 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 91 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 165 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2011 | 86 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 113 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 125 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 4700 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 412 | 0.020 |
Why?
|
| Adipokines | 1 | 2011 | 119 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 274 | 0.020 |
Why?
|
| Serine | 1 | 2011 | 161 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 567 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2547 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1243 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1800 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5049 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 946 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2011 | 558 | 0.020 |
Why?
|
| Pedigree | 2 | 2006 | 1670 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 686 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2063 | 0.020 |
Why?
|
| Actinin | 1 | 2006 | 7 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1995 | 889 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2006 | 254 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1027 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2006 | 166 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3752 | 0.010 |
Why?
|
| Base Sequence | 2 | 1998 | 2730 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 195 | 0.010 |
Why?
|
| Werner Syndrome Helicase | 1 | 1997 | 2 | 0.010 |
Why?
|
| Exodeoxyribonucleases | 1 | 1997 | 52 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 1998 | 198 | 0.010 |
Why?
|
| RecQ Helicases | 1 | 1997 | 61 | 0.010 |
Why?
|
| Homozygote | 1 | 1997 | 533 | 0.010 |
Why?
|
| DNA Probes | 1 | 1995 | 117 | 0.010 |
Why?
|
| DNA Repair | 1 | 1998 | 570 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1997 | 508 | 0.010 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1995 | 40 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 242 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 1605 | 0.010 |
Why?
|
| Point Mutation | 1 | 1995 | 332 | 0.010 |
Why?
|
| Phenotype | 1 | 1997 | 4459 | 0.000 |
Why?
|